Israeli startup Synchrony Medical Ltd. is gearing up to begin a U.S. clinical trial testing an airway clearance method developed at Israel’s Sheba Medical Center. The Libairty device is designed to support chronic lung disease patients to clear mucus with a short home-based daily treatment.
Two Israeli companies aiming to improve in vitro fertilization (IVF) success rates received good news recently, with Aivf Ltd. hauling in $25 million in a series A round for Ema, its IVF software platform, and Fairtility Ltd. gaining CE mark for its CHLOE EQ embryo quality decision-support tool.
Proving that reproduction remains a fecund market for investment, Israeli startup Fairtility Ltd. closed a $15 million series A funding round. Led by Boston-based Gurnet Point Capital with support from Nacre Capital and others, the round boosted Fairtility’s funding to date up to $18.5 million.
Pharma and tech companies including Amazon Inc., Astrazeneca plc, Pfizer Inc., Merck & Co. Inc. and Teva Inc. are partnering with an innovation lab based in Israel to accelerate artificial intelligence (AI) driven antibody discovery. Rehovot, Israel-based Aion Labs recently launched a venture hub for innovators and scientists from around the world.
Following the termination of a planned merger with SPAC Medtech Acquisition Corp., Tel Aviv-based Memic Innovative Surgery Ltd. is looking to slowly roll out its Hominis surgical platform. Nasdaq-listed SPAC Medtech and Memic called off the agreement due to “market volatility and world events.”
In the post COVID world, digital transformation is at the forefront of every company’s agenda, but which innovations can fuel the next era of health care? At the ongoing Biomed Israel conference in Tel Aviv, Anat Naschitz founder and CEO of 9xchange and co-founder of Orbimed Israel, lead a digital health track exploring the technologies aiming to reconstruct the future of health care.
Ten years from now, what medical technologies will generate the most economic value and where is the industry heading? At the annual Biomed Israel conference, held in Tel Aviv, health care, pharmaceutical and technology advisor, and board director Sandra Morgan examined research from consulting firm McKinsey & Co. and beyond on the biggest innovation trends in the sector.
At the annual Biomed Israel conference, held in Tel Aviv, Eyal Lifschitz, co-founder of Israeli venture capital fund Peregrine Venture, urged entrepreneurs to adapt their business strategy or face a long, difficult road to exit. With strategic companies increasingly favoring companies later in development, Lifschitz advised innovators to expand their vision beyond the traditional buyers.
With cancer treatment success rates rising, the field of precision oncology is poised to grow as clinicians aim to move treatment from a one size fits all approach to personalized treatment regimens. Israeli startups including Oncohost Ltd., Nucleai Ltd. and Gina Life Diagnostics Ltd. are part of an emerging wave of companies utilizing artificial intelligence (AI) and machine learning (ML) techniques to personalize the future of cancer diagnostics.
Newstem Ltd. filed a presubmission to the U.S. FDA for a de novo request and an in vitro diagnostic device with the EMA for its Newstem software diagnostic device (NSDD). The bioinformatics-based platform is a personalized diagnostic to inform oncologists about the presence of mutations in tumors and predict a patients’ resistance to chemotherapy treatments. The technology utilizes specialized stem cells (haploid cells) that carry just one set of chromosomes.
RSS
